This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

TranS1 Inc. Announces Agreement To Acquire Baxano, Inc. And $17.2M Financing Commitment

Conference Call to be Held on March 4, 2013 at 8:30 a.m. EST

Combination Adds Rapidly Growing Minimally Invasive Spinal Decompression Technology and Large Surgeon User Base

Baxano Shareholders Commit $15.3M in Concurrent Financing

RALEIGH, N.C., March 4, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a medical device company focused on designing, developing and marketing products to treat degenerative conditions of the spine affecting the lumbar region, today announced that it has entered into a definitive agreement to acquire Baxano, Inc., a privately-held medical device company that manufactures and markets the iO-Flex® system utilized in standard spinal decompression surgery and is developing the iO-Tome TM system, a precision facetectomy instrument.

Merger Transaction

Under the terms of the merger agreement (the "Merger Agreement"), TranS1 Inc. ("TranS1" or "the Company") will issue approximately 10.4 million shares of TranS1 Common Stock and pay $550,000 of cash (approximately $23.6 million of value based on the March 1, 2013 closing price) to acquire Baxano, Inc. ("Baxano") (the "Merger Transaction"). The Company will also refinance $3.0 million of existing debt of Baxano in the transaction at closing. On a pro forma basis, prior to the financing transaction discussed below, current TranS1 shareholders will own approximately 72.4% of the combined company and approximately 27.6% will be owned by current Baxano shareholders. The final number of shares will be subject to certain adjustments at closing. The Merger Transaction is currently expected to close early in the second quarter of 2013 and is subject to TranS1 shareholder approval and customary conditions to closing as detailed in the Merger Agreement.

The Company believes that the strategic merit of the combined business includes the following benefits to its shareholders:
  • Expands focus on minimally invasive lumbar spine treatments, with a combined addressable market opportunity of $3.9B
  • Complements existing proprietary product portfolio with differentiated patented products
  • Broadens sales force coverage and provides significant cross-selling opportunities within the MIS surgeon customer focus
  • Improves financial profile

"We believe that Baxano is a complementary strategic fit for our product portfolio," said Ken Reali, President and Chief Executive Officer of TranS1. "Minimally invasive treatments are the fastest growing segment of the spine market. The combination of our AxiaLIF® and VEO TM lumbar fusion products with Baxano's iO-Flex and iO-Tome systems for lumbar direct decompression and facetectomy, respectively, will allow us to better meet the needs of our spine surgeon customers. This merger will create a unique company with the vision of being a leader in providing less invasive and minimally invasive solutions for spine disorders."

"We are enthusiastic about the combination of Baxano with TranS1," said Tony Recupero, President and Chief Executive Officer of Baxano. "We believe the combined company will have a compelling set of minimally invasive products to benefit patients, surgeons, hospitals and payors and will continue to build on the positive sales momentum we have built at Baxano over the past few years."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $92.96 -0.70%
FB $118.11 0.04%
GOOG $699.12 0.49%
TSLA $213.76 -4.00%
YHOO $37.11 3.10%


Chart of I:DJI
DOW 17,693.00 +41.74 0.24%
S&P 500 2,054.48 +3.36 0.16%
NASDAQ 4,733.0830 +7.4440 0.16%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs